Maki Komiyama

National Hospital Organization, Kyoto Medical Center, Japan

Articles

Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?

Maki Komiyama, Koji Hasegawa, Akira Matsumori, et al

Published:

Citation: European Cardiology Review 2020;15:e49.

Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019’

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e55.

Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e58.

Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e16.

Obesity and Cardiovascular Risk After Quitting Smoking: The Latest Evidence

Koji Hasegawa, Maki Komiyama, Yuko Takahashi, et al

Published:

Citation: European Cardiology Review 2019;14(1):60–1

ISCP Guest Editorial: Cardiovascular Disease Prevention in Diabetes

Maki Komiyama, Koji Hasegawa,

Citation: European Cardiology Review 2018;13(1):21–2.

Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

Maki Komiyama, Hiromichi Wada, Hajime Yamakage, et al

Citation: European Cardiology Review 2017;12(2):96.

Analysis of Factors Associated with Smoking Relapse

Sayaka Shimada, Maki Komiyama, Hiromichi Wada, et al

Citation: European Cardiology Review 2017;12(2):111.